🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

And the #iwMDS24 officially starts with Amer Zeidan MBBS,MHS ‏عامر زيدان explaining feats achieved and efforts ongoing in the MDS realm under the purview of International Consortium for MDS (icMDS) first session chaired by Dr. Uma Borate: Associate Professor and Dr Savona

Happening now! Dr. Michael Savona Vanderbilt University Medical Center @VUMC_Cancer delivering a fantastic state of the art overview of #CHIPsm and #CCUS International Consortium for MDS (icMDS) VJHemOnc #iwMDS meeting in Boston! Ashwin Kishtagari, MD Alex Bick #CHIVE Amer Zeidan MBBS,MHS ‏عامر زيدان Dr. jordan berlin

Fascinating to see expanding use of #AI from classification, risk stratification to Rx response prediction led by none other than Dr. Della Porta in exceptional #keynote talk International Consortium for MDS (icMDS) VJHemOnc #iwMDS #PersonalizedMedicine Rami komrokji Amer Zeidan MBBS,MHS ‏عامر زيدان Sanam Loghavi, MD صنم لغوی 🔬🧬 GenoMed4All

The shadowlands between hMDS, BMF and inherited BMF. Kudos to Emma M. Groarke from NIH NHLBI at #iwMDS24 International Consortium for MDS (icMDS) rising ⭐️ session

Delighted to share our latest story!📰 Prognostic and therapeutic implications of #TP53 expression in chronic myelomonocytic leukemia #CMML nature.com/articles/s4140… 🧵 #MDSsm #MPNsm Blood Cancer Journal 🙏 Andrés Jerez Kiran Batta @dwiseman78 CRUK Manchester Institute Division of Cancer Sciences #NTUH OncoDaily

Our 2nd International Consortium for MDS (icMDS) meeting in Boston (#iwMDS/MPN) was very successful w steady progress in achieving our 10 top priority research goals (2022-2032) released w 1st meeting in 2022. We remain united & committed to productive collaborations between all stakeholders #MDSsm VJHemOnc

The prelim version of our icMDS paper “contemporary approach to the diagnosis & classification of MDS” is online in Modern Pathology 🙏🏻 to our 52 co-authors & shoutout to first author Aakash Bhatia, MD hope you find it helpful in your #hemepath practice sciencedirect.com/science/articl…

Data-driven, harmonised classification system for MDS sciencedirect.com/science/articl… It took a global effort for this project using largest MDS cohort to date from Moffitt and Genomed datasets. Thx to all my dear coauthors Moffitt Cancer Center Amer Zeidan MBBS,MHS ‏عامر زيدان Somedeb Ball GenoMed4All International Consortium for MDS (icMDS)

It was an honor to co-lead this global effort on behalf of #MDSsm community! Learned a lot in process. Forever thankful to Rami komrokji for the opportunity. Hope our framework paves way for future WHO/ICC harmonization Amer Zeidan MBBS,MHS ‏عامر زيدان @LucaLanino International Consortium for MDS (icMDS) @VUMCHemOnc @VUMC_Cancer

In 2022, ⁦International Consortium for MDS (icMDS)⁩ issued a statement highlighting negative consequences of having 2 classifications for #MDSsm, we then took to action & developed a data-driven, harmonized classification system. Every system has shortfalls, but we need ONE system sciencedirect.com/science/articl…

Another important initiative that International Consortium for MDS (icMDS) took on is providing a consistent frame for process of diagnosing, classifying and reporting path results of #MDSsm. Two important papers under leadership of doctors Sanam Loghavi, MD صنم لغوی 🔬🧬 & Mina L Xu (below is 1st paper, 2nd to be published soon)

Kicking off 2025 with this outstanding International Consortium for MDS (icMDS) first online @BloodJournal effort that every clinical researcher, regulator, industry sponsor, reviewer, or anyone involved involved in #MDSsm clinical trials should read before writing or approving an #MDSsm clinical trial protocol

Publication alert 👉👉👉 on behalf of the International Consortium for MDS (icMDS) in @BloodJournal , 'Reducing Clinical Trial Eligibility Barriers for MDS :An icMDS Position Statement'. This paper demonstrates how eligibility criteria for LR & HR MDS often do not vary across trial phases & don't reflect known

New data out! Prof Raaijmakers addressed the stromal niche contributions to MDS pathogenesis at #ESHMICRO2025 ! #MDSsm AA&MDSIF MDS Foundation MDS Hub International Consortium for MDS (icMDS)

Dr Ioannis Aifantis Iannis Aifantis shared his lab's obsession: bio-geography, cellular diversity and natural selection in AML! #ESHMICRO2025 #ESHCONFERENCES #leusm #RAS #myeloid #sarcoma AML Hub

Congratulations to our prior fellow, now assistant professor Savanah Gisriel, MD, MPH on the new manuscript standardizing marrow diagnoses for MDS. Thank you Amer Zeidan MBBS,MHS ‏عامر زيدان for the vision and International Consortium for MDS (icMDS) for coming to clinical, pathologic, inter-institutional consensus. pubmed.ncbi.nlm.nih.gov/40059041/

Thrilled to see our effort on behalf of International Consortium for MDS (icMDS) group out in Blood Journal about reducing clinical trial eligibility barriers for our MDS patients. Commentary by Lionel Ades on ‘ releasing the brake’ on eligibility criteria. Amer Zeidan MBBS,MHS ‏عامر زيدان #mdssm ashpublications.org/blood/article/…

Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent MDS or CMML nature.com/articles/s4140… #MDSsm #leusm #CMML MDS Foundation AA&MDSIF International Consortium for MDS (icMDS) MDS Hub AML Hub

Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes ascopubs.org/doi/10.1200/JC… #MDSsm #TP53 Journal of Clinical Oncology MDS Foundation AA&MDSIF International Consortium for MDS (icMDS) MDS Hub